Positive News SentimentPositive NewsNASDAQ:INDP Indaptus Therapeutics (INDP) Stock Price, News & Analysis $1.76 +0.32 (+22.22%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$1.76 0.00 (0.00%) As of 05/29/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Indaptus Therapeutics Stock (NASDAQ:INDP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Indaptus Therapeutics alerts:Sign Up Key Stats Today's Range$1.44▼$1.8450-Day Range$1.06▼$3.6152-Week Range$0.92▼$19.91Volume102,221 shsAverage Volume94,197 shsMarket Capitalization$199.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Indaptus Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease. Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors. The company is also exploring applications in antiviral immunotherapies, reflecting the versatility of its platform. By combining advanced engineering techniques with scalable manufacturing processes, Indaptus aims to deliver off-the-shelf therapies to patients with unmet medical needs. Headquartered in the United States, Indaptus collaborates with academic institutions and contract research organizations to advance discovery and clinical translation. Since its inception, the company has established state-of-the-art research and development facilities to support process development, preclinical evaluation, and future clinical manufacturing. Led by a management team with deep experience in cell and gene therapy development, Indaptus is positioned to move its lead programs into early-phase clinical trials and expand its strategic partnerships in the biopharmaceutical industry.AI Generated. May Contain Errors. Read More Indaptus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreINDP MarketRank™: Indaptus Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 790th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingIndaptus Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageIndaptus Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Indaptus Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Indaptus Therapeutics is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Indaptus Therapeutics is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIndaptus Therapeutics has a P/B Ratio of 176.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Indaptus Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.07% of the float of Indaptus Therapeutics has been sold short.Short Interest Ratio / Days to CoverIndaptus Therapeutics has a short interest ratio ("days to cover") of 0.94, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indaptus Therapeutics has recently decreased by 14.61%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIndaptus Therapeutics does not currently pay a dividend.Dividend GrowthIndaptus Therapeutics does not have a long track record of dividend growth. News and Social Media4.3 / 5News SentimentN/A News SentimentIndaptus Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Indaptus Therapeutics this week, compared to 1 article on an average week.Search Interest8 people have searched for INDP on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Indaptus Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Indaptus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders23.60% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions7.06% of the stock of Indaptus Therapeutics is held by institutions.Read more about Indaptus Therapeutics' insider trading history. Receive INDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INDP Stock News HeadlinesIndaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | globenewswire.comIndaptus Therapeutics Adds Independent Directors Amid Board RefreshApril 23, 2026 | tipranks.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.May 30 at 1:00 AM | Profits Run (Ad)Indaptus Therapeutics Appoints David Natan to BoardJanuary 8, 2026 | tipranks.comIndaptus Therapeutics announces upcoming board leadership transitionJanuary 3, 2026 | msn.comIndaptus Therapeutics enters $6M securities purchase agreement with David LazarDecember 29, 2025 | msn.comIndaptus Therapeutics stock falls after $6 million securities dealDecember 29, 2025 | za.investing.comWhy did INDP stock gain 12% today?December 29, 2025 | msn.comSee More Headlines INDP Stock Analysis - Frequently Asked Questions How have INDP shares performed this year? Indaptus Therapeutics' stock was trading at $2.91 on January 1st, 2026. Since then, INDP stock has decreased by 39.5% and is now trading at $1.76. How were Indaptus Therapeutics' earnings last quarter? Indaptus Therapeutics, Inc. (NASDAQ:INDP) released its earnings results on Friday, May, 15th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($1.87) by $1.64. When did Indaptus Therapeutics' stock split? Shares of Indaptus Therapeutics reverse split on Friday, June 27th 2025.A 1-28 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Indaptus Therapeutics IPO? Indaptus Therapeutics (INDP) raised $0 in an initial public offering (IPO) on Tuesday, August 4th 2015. The company issued 0 shares at a price of $0.00 per share. How do I buy shares of Indaptus Therapeutics? Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Indaptus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Indaptus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), GE Aerospace (GE), Meta Platforms (META), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings5/15/2026Today5/30/2026Next Earnings (Estimated)8/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 9 days, INDP's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INDP CIK1857044 Webintecpharma.com Phone(646) 427-2727Fax972-2586-9176Employees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)($15.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,030.07% Return on Assets-299.69% Debt Debt-to-Equity RatioN/A Current Ratio2.34 Quick Ratio2.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book176.00Miscellaneous Outstanding Shares113,240,000Free Float86,517,000Market Cap$199.30 million OptionableNot Optionable Beta1.37 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:INDP) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...Behind the Markets | SponsoredMusk takes on IranIranian drones have struck Amazon's data centers, with Microsoft, Google, Oracle, and Nvidia reportedly next o...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INDP Stock Alerts